ALNY is the ticker symbol for ALNYLAM PHARMACEUTICALS, INC., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks ALNY with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is ALNY a good stock to buy?

13F Pro's AI ranking engine scores ALNY at 72.5/100, ranked #146 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for ALNY is available at https://13fpro.ai/company/ALNY. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source ALNY data?

All ALNYLAM PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. ALNYLAM PHARMACEUTICALS, INC. files with the SEC under CIK 1178670. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

ALNYLAM PHARMACEUTICALS, INC. ALNY

NasdaqLarge CapHealthcare

13F Pro quality score

Rank #146 of 2,925TOP 5%

Why it scores 73 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$1.29B

Quarter to Jun 30

Net income

$164.49M

Quarter to Jun 30

Operating margin

17.9%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$40.51B total

FMR LLC

$4.54B-2.7%

Capital World Investors

$3.36B+16.9%

BlackRock, Inc.

$3.29B-30.1%

Capital Research Global Investors

$2.94B+3.0%

VANGUARD PORTFOLIO MANAGEMENT LLC

$1.97B+0.7%

VANGUARD CAPITAL MANAGEMENT LLC

$1.82B+1.4%

T. Rowe Price Investment Management, Inc.

$1.70B+8.6%

Invesco Ltd.

$1.13B+38.6%

STATE STREET CORP

$1.08B-50.8%

GEODE CAPITAL MANAGEMENT, LLC

$791.35M-0.9%

JPMORGAN CHASE & CO

$789.11M-20.5%

BAILLIE GIFFORD & CO

$734.48M-2.2%

NORGES BANK

$683.88M--

WELLINGTON MANAGEMENT GROUP LLP

$635.30M+9.0%

Orbis Allan Gray Ltd

$598.27M+48.9%

DODGE & COX

$588.63M+1.4%

TWO SIGMA INVESTMENTS, LP

$564.71M-76.5%

AMERICAN CENTURY COMPANIES INC

$558.10M+2.9%

Clearbridge Investments, LLC

$379.14M-7.1%

PRICE T ROWE ASSOCIATES INC /MD/

$345.94M-19.8%

D. E. Shaw & Co., Inc.

$332.37M+4.3%

BANK OF AMERICA CORP /DE/

$321.91M+66.3%

MORGAN STANLEY

$312.78M-33.2%

MANUFACTURERS LIFE INSURANCE COMPANY, THE

$285.57M+1.6%

Legal & General Group Plc

$278.32M-1.1%

See all 811 institutional holders →

What's Driving ALNY's Business? Latest 10-Q Breakdown

30/30 datapoints verified

AI-extracted from the 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenue rose 67% to $1.29B as AMVUTTRA reached $1.01B (+106% YoY), producing $164.5M net income versus a $72.2M loss a year ago.

Biggest Revenue Drivers

Net product revenues$1.17B+74% YoY

Growth from AMVUTTRA driven by increased patient demand, mainly in patients with ATTR-CM in the U.S.

Royalty revenue$71.7M+79% YoY

Increased volume and rate of royalties earned from global net sales of Leqvio by Novartis

Biggest Revenue Drivers

Total revenue: $1.29B+67% YoY

Net product revenues$1.17B+74% YoY

Growth from AMVUTTRA driven by increased patient demand, mainly in patients with ATTR-CM in the U.S.

Within Net product revenues

AMVUTTRA$1.01B+106% YoY

U.S. sales of $809.1M, up 124%, following ATTR-CM approval

Total Rare (GIVLAARI & OXLUMO)$141.9M+11% YoY

Growth from an increased number of patients on GIVLAARI and OXLUMO

Royalty revenue$71.7M+79% YoY

Increased volume and rate of royalties earned from global net sales of Leqvio by Novartis

Net revenues from collaborations$47.2M-23% YoY

Lower Regeneron revenue on completed activities and wind-down of the Initial Research Term, partly offset by Roche ZENITH reimbursements

Largest Expense Items

Research and development$413.1M+28% YoY

Increased clinical trial expenses for ZENITH, TRITON-CM and TRITON-PN Phase 3 trials, partly offset by KARDIA wind-down and lower stock-based compensation

Selling, general and administrative$347.9M+8% YoY

Increased marketing investment for the global AMVUTTRA ATTR-CM launch and higher IT infrastructure costs, partly offset by lower stock-based compensation

Cost of goods sold$298.3M+110% YoY

Increased sales of AMVUTTRA and an associated increase in the blended royalty rate payable on AMVUTTRA net sales

Margins: Cost of goods sold rose to 25.4% of net product revenues from 21.1%, on higher AMVUTTRA sales and a higher blended Sanofi royalty rate; management expects that percentage to keep rising in 2026.

Watch Items from the Filing

Sanofi royalty tiers on AMVUTTRA escalate with volume: 25% of global annual net sales from $500.0M to $1.50B and 30% above $1.50B, compressing gross margin as sales scale.
October 2025 subpoena from the U.S. Attorney's Office for Massachusetts seeks documents on government price reporting for AMVUTTRA, ONPATTRO, OXLUMO and GIVLAARI; no loss contingency accrued.
AMVUTTRA is $1.01B of $1.17B net product revenues; ONPATTRO fell 65% to $18.5M, leaving revenue concentrated in one product.
Regeneron collaboration revenue fell 85% to $5.0M as the Initial Research Term expired in May 2026; no additional targets will be added to the collaboration.
If Blackstone Royalties does not receive $1.00 billion of Leqvio royalties by December 31, 2029, its royalty interest rises from 50% to 55% beginning January 1, 2030.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ALNY

Earnings Per Share

13fpro.ai/company/ALNY

Loading ratio trend…

ALNYLAM PHARMACEUTICALS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$3.7B	$313.7M	13.5%
FY 2024	10-K	$2.2B	$-278.2M	-7.9%
FY 2023	10-K	$1.8B	$-440.2M	-15.4%
FY 2022	10-K	$1.0B	$-1.1B	-75.7%
FY 2021	10-K	$844.3M	$-852.8M	-83.9%
FY 2020	10-K	$492.9M	$-858.3M	-168.1%

About ALNYLAM PHARMACEUTICALS, INC. (ALNY): stock profile, AI score and financials

ALNYLAM PHARMACEUTICALS, INC. (ALNY) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALNY at 72.5/100 on a composite quality score built from its SEC filings, placing it at rank #146 of 2,925 stocks — the top 5% of the AI-ranked universe. ALNY scores in the top quartile across balance sheet strength (92.4), revenue growth (92.3), profitability (80.9). Shareholder dilution risk is elevated at 16.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), ALNYLAM PHARMACEUTICALS, INC. reports quarterly revenue of $1.3B, net income of $164.5M, an operating margin of 17.9%. Top institutional holders of ALNY by reported 13-F value include FMR, Capital World Investors, BlackRock, based on the most recent SEC filings. ALNY trades on the Nasdaq exchange and files with the SEC under CIK 1178670. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALNY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALNYLAM PHARMACEUTICALS, INC. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1178670 →

ALNYLAM PHARMACEUTICALS, INC. ALNY

Top Institutional Holders

What's Driving ALNY's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

ALNY key financials by period

ALNY insiders

Congress trading in ALNY

About ALNYLAM PHARMACEUTICALS, INC. (ALNY): stock profile, AI score and financials

ALNYLAM PHARMACEUTICALS, INC. ALNY

Top Institutional Holders

What's Driving ALNY's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

ALNY key financials by period

Companies similar to ALNY

ALNY insiders

Congress trading in ALNY

About ALNYLAM PHARMACEUTICALS, INC. (ALNY): stock profile, AI score and financials